AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another therapy.
https://www.pharmalive.com/wp-content/uploads/2021/01/Enhertu-Business-Wire-1-17-21-.jpg36354746Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-08-15 10:18:442022-08-15 11:04:11AstraZeneca says data confirms Enhertu benefit in breast cancer patients
